focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,783.50
Bid: 1,780.00
Ask: 1,780.50
Change: -29.00 (-1.60%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,775.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Defensive stocks buoy FTSE 100 before U.S.-China trade deal

Wed, 15th Jan 2020 09:20

* FTSE 100 up 0.3%, FTSE 250 down 0.2%

* U.S. tariffs on China to remain in place for now

* Tullow Oil drags midcaps lower

* Banks drop on rate cut bets
(Adds company news items, updates to closing prices)

By Shashwat Awasthi and Muvija M

Jan 15 (Reuters) - London's main share index rose slightly
on Wednesday, hours before the sealing of an initial U.S.-China
trade deal, though sentiment was tempered when Washington said
tariffs on Chinese goods would not be rolled back immediately.

The FTSE 100 rose 0.3% on a third day of gains,
supported by a host of so-called defensive stocks including
pharmaceutical giants AstraZeneca and GlaxoSmithKline
, which rose nearly 2%, and consumer goods companies.

Investors tend to turn to these sectors at times of
macroeconomic uncertainty.

The FTSE 250 ended 0.2% lower, with a 16% plunge in
Tullow Oil weighing the most. Tullow said it would take
a $1.5 billion writedown after cutting its long-term oil price
assumptions.

Investors betting on a quick de-escalation of Sino-American
tensions were dealt a blow when U.S. Treasury Secretary Steven
Mnuchin said tariffs on Chinese goods would not be repealed
until the completion of a Phase 2 agreement.

"Strategic competition between the U.S. and China,
especially in tech, is likely to persist despite a limited
'Phase 1' trade deal," BlackRock analysts wrote in their weekly
note.

"The U.S.-China trade conflict – 2019's dominant
geopolitical risk – has paused, yet we expect enduring strategic
rivalry between the two countries."

Banks suffered across the board as weak inflation data
further spurred hopes that the Bank of England will cut interest
rates in its January meeting. Low interest rates squeeze a
lender's margins.

Royal Bank of Scotland, which also had its rating
downgraded by Barclays, led the sub-index down 1%
to a one-month low with a 2.5% share price fall.

Keeping a lid on losses on the midcap bourse, Provident
Financial jumped 7% after its key credit card business
enjoyed a better-than-expected fourth quarter and Hochschild
Mining climbed 3% on better-than-expected 2019
production.

Among smaller stocks, fast fashion retailer QUIZ
tanked nearly 20% on its worst day since June, as it pointed to
poor trading over the key Christmas period.
(Reporting by Shashwat Awasthi and Muvija M in Bengaluru,
Editing by Sherry Jacob-Phillips and Shailesh Kuber)

More News
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.